TGF-β-driven reduction of CYGB is associated with oxidative DNA damage of HSCs in NASH

April 21, 2020

In the 2020 April 21 issue of Journal of Hepatology, a research group from the Department of Hepatology in Osaka City University Graduate School of Medicine, Japan reported that a new insight into the pathophysiology of human nonalcoholic steatohepatitis (NASH) with fibrosis and suggested a possibility of the new therapy using cytoglobin (CYGB) inducer for clinical application.

Liver fibrosis is a common pathological feature of chronic liver diseases including virus infection, alcohol-related damage and metabolic syndromes, ultimately progresses to cirrhosis and increases the risk of developing hepatocellular carcinoma.

Although the number of patients with viral hepatitis has been reduced due to the development of antiviral therapy, NASH with liver fibrosis caused by metabolic syndrome has been increasing in recent years. However, evidence-based treatment for pathophysiology of NASH with liver fibrosis has not been established yet.

When the liver is damaged, hepatic stellate cells (HSCs), one of the liver constituent cells, are activated and collagen production is accelerated. If the cause is not eliminated, it progresses to cirrhosis, which causes scarring of tissues and markedly reduces liver function.

Moreover, severe hepatic fibrosis and hepatocellular carcinoma are estimated to cause 3.5% of all deaths worldwide, indicating a need for new anti-fibrotic therapies based on a detailed mechanistic understanding of liver diseases.

Therefore, activated HSCs have recently been focused on as a target cell for anti-fibrotic therapy and research on HSC is being actively worked worldwide.

It is widely accepted that transforming growth factor beta (TGF-β), is a cytokine, triggers strongly fibrogenic response through activation of HSCs.

CYGB is a mammalian globin, which is discovered by researchers and uniquely expresses in HSCs in the liver. Previously, researchers have reported that CYGB suppresses liver damage caused by oxidative stress and is expected to has a protective effect on hepatic parenchymal cells.

This study shows that the molecular regulatory mechanism of TGF-β-induced downregulation of CYGB in human HSCs, leading to the loss of cellular tolerance to exogenous oxidative stress and oxidative DNA damage in activated HSCs in human NASH with advanced fibrosis. Moreover, researchers revealed the new function of CYGB for the first time that CYGB can inhibit oxidative DNA damage by scavenging hydroxyl radicals.

Osaka City University

Related Liver Fibrosis Articles from Brightsurf:

Eating less suppresses liver cancer due to fatty liver
Liver cancer from too much fat accumulation in the liver has been increasing in many countries including Japan.

New insights into mechanism of therapy to reduce liver fat and prevent fibrosis
A team led by researchers at Massachusetts General Hospital (MGH) has taken an important step forward in the goal of developing a potential treatment for non-alcoholic fatty liver disease.

Closing in on liver fibrosis: Detailing the fibrosis process at unprecedented resolution
Today, there is no effective way to treat liver fibrosis.

Liver fibrosis tied to specific heart failure, regardless of HIV or hepatitis C status
While there is an association between liver fibrosis and heart failure, the mechanisms for this association are currently unclear but may be of particular importance for people living with human immunodeficiency virus (HIV) and/or hepatitis C, both of which are chronic infections that affect the liver and heart.

Researchers find test to ID children at higher risk for cystic fibrosis liver disease
A major multi-center investigation of children with cystic fibrosis has identified a test that allows earlier identification of those at risk for cystic fibrosis liver disease.

Yale studies suggest new path for reversing type-2 diabetes and liver fibrosis
In a pair of related studies, a team of Yale researchers has found a way to reverse type-2 diabetes and liver fibrosis in mice, and has shown that the underlying processes are conserved in humans.

Liver fibrosis 'off switch' discovered in mice
UC San Diego School of Medicine researchers identified several genetic switches, or transcription factors, that determine whether or not liver cells produce collagen -- providing a new therapeutic target for liver fibrosis.

Magnetic nanomaterials become an effective treatment against liver fibrosis
Fibrosis may affect different body organs. It develops as a reaction to long-time inflammation and is supposed to isolate the inflammation site from surrounding tissues.

Cystic fibrosis carriers are at increased risk for cystic fibrosis-related conditions
A University of Iowa study challenges the conventional wisdom that having just one mutated copy of the cystic fibrosis (CF) gene has no effects on a person's health.

Longevity protein SIRT6 also protects against fatty liver and fatty liver disease
SIRT6 regulates fat metabolism by activating another protein called peroxisome proliferator-activated receptor alpha (PPAR-alpha).

Read More: Liver Fibrosis News and Liver Fibrosis Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to